US Stock Market Move | The previously announced weight loss drug Cagrisema data caused Novo Nordisk A/S Sponsored ADR Class B (NVO.US) to fall more than 8%.

On Monday, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) opened with a drop of over 8%, at $80.10. In terms of news, data shows that CagriSema from Novo Nordisk A/S Sponsored ADR Class B resulted in a 15.7% weight loss in patients after 68 weeks, compared to the market's expectation of 20%. In comparison, the placebo group only experienced a 3.1% weight loss. Novo Nordisk A/S Sponsored ADR Class B is expected to apply for the first regulatory approval for CagriSema in the first quarter of 2026.